Patients Discontinuing Anti-Obesity Medications Gain Back Weight at a Quadrupled Rate Than People Using Diet and Exercise

A recent study indicates that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.

Findings released in a leading health publication demonstrates that while overweight individuals can lose substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month after stopping.

"Users buying these medications should be cognizant of the danger of fast rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.

That rate of recovery means a return to original mass in about a year and a half.

Weighing Approaches

The research, which reviewed dozens of trials involving thousands of patients, compared the results of the injectable medications with conventional dieting.

Researchers emphasize that people who lose weight through dieting typically have a slower weight regain—around 100 grams monthly—after stopping.

The Reason for the Fast Rebound

Nutrition scientists propose the mode of action of the jabs accounts for the heightened regain.

The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.

"Withdrawal of this medication means appetite is no longer kept in check, making overeating far more likely."

A Chronic Condition?

The NHS recommend the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.

A number of clinicians say that, considering the likelihood of relapse, the treatment is often long-term.

This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the long-term character of excess weight," comparing it to managing conditions like diabetes.

Patient Experiences

Users who have discontinued the medication explain a sudden return of hunger.

"It felt as if a trigger flipping and you become starving," recalled an individual.

This challenge is worsened if patients have not developed sustainable dietary or behavioural changes during therapy.

Growing Adoption

Survey data indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.

• Adoption is higher among women compared to males.
• The 40s and 50s age group shows the highest level of interest.
• Many obtain the drugs through private healthcare rather than public health services.

Ultimately, researchers caution that while the jabs are effective tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on ongoing behavioural support.